Genelux (GNLX)

• Market cap: $123M
• 1 day: 2.62%
• 5 days: 7.45%
• 1 month: 7.03%
• 3 months: 0.37%
• 6 months: -66.75%
• Year to date: -39.78%
• 1 year: 12.76%
• 5 years: -55.45%
• 10 years: -55.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Employees: 26